Baseline demographic and clinical characteristics of the patients. Data are number (%) unless otherwise indicated.
| ABA-1, n = 14 | ABA-2, n = 17 | p | |
|---|---|---|---|
| Sex (F:M) | 1 :2 | 17:0 | 0.196 |
| Age at treatment start, yrs, mean (SD), range | 8.7 (3.4), 3.1–14.6 | 12.6 (4.9), 5.0–23.8 | 0.015 |
| Age at uveitis onset, yrs, mean (SD), range | 4.8 (3.3), 1.3–13.6 | 4.2 (2.0), 2.0–9.5 | > 0.999 |
| Uveitis duration at ABA start, yrs, mean (SD), range | 3.8 (3.2), 1–10.8 | 7.4 (5.2), 1.4–17.7 | 0.007 |
| Uveitis relapses 12 mo pre-ABA, mean (SD), range | 4.1 (2.3), 1.0–8.0 | 3.7 (3.0), 1.0–12.0 | 0.387 |
| Complicated uveitis* | 7/14 (50.0) | 10/17 (58.8) | 0.785 |
| Previous anti-TNF-α treatments | |||
| Etanercept | — | 5 (29.4) | — |
| Infliximab | — | 11 (64.7) | — |
| Adalimumab | — | 17 (100) | — |
| Corticosteroids/DMARD (MTX) | 8 | 10 | 0.925 |
| Only DMARD (MTX, CSA, MMF) | 6 | 7 |
↵* Complicated uveitis: the occurrence of 1 or more structural complications such as posterior synechiae (involving at least 1 iris quadrant), band keratopathy, cataract, cystoid macular edema, or ocular hypertension. ABA: abatacept; DMARD: disease-modifying antirheumatic drugs; TNF: tumor necrosis factor; MTX: methotrexate; MMF: mycofenolate mofetil; CSA: cyclosporine.